## **PEDIATRIC** PRESCRIPTION AND SERVICE REQUEST FORM SIMLANDI® (adalimumab-ryvk) injection

## **teva** | Shared Solutions® for Biosimilars

#### **ENROLLMENT FORM**

PLEASE FAX COMPLETED FORM TO 866-676-4073
FOR QUESTIONS, CALL 888-587-3263

MONDAY-FRIDAY 9AM EST TO 7PM EST

Requested Services:		n	ng Prior Authorization S	upport 🗌 Co	ommercial Co	pay Program					
1 PEDIAT	RIC PATIENT IN	FORMATION (PARENT/CA	AREGIVER/LEGAL REP TO	COMPLETI	E SECTIONS	5 1-3)					
Patient Name (First MI Last):		DOB (mm/dd/yyyy):									
Primary Phone:				Gender: ☐ Male ☐ Female ☐ Other							
Email:		Preferred Time of contact:	ning  Afternoon	Preferred Langu	age: 🗌 English	☐ Spanish ☐ Other					
May we leave a detailed voi	cemail on your persona	l cell phone about the status of y	our application, prescription	ı, or shipment	s? 🗌 Yes	□No					
May we leave a detailed voicemail on your personal cell phone about the status of your application, prescription, or shipments? $\square$ Yes $\square$ No Is it okay to send text messages to your mobile device regarding the status of your application, prescription, or shipments? $\square$ Yes $\square$ No											
By selecting Yes, I agree to receive text messages as allowed by this Form to the cell phone number provided. Message and data rates may apply.											
Address:			City:		State:	ZIP:					
Parent/Caregiver/Legal Rep Name	Contact Phone (if applicable):										
			11								
2 INCUR	ANCE INCORAG	TION									
2 INSURANCE INFORMATION											
	☐ Private Commercial ☐ Medicare ☐ Medicaid ☐ VA **PLEASE INCLUDE COPIES OF INSURANCE CARDS, FRONT AND BACK**										
Primary Insurance Name:	G		Rx Insurance Name:  Rx ID#:		Craum #						
Primary Insurance Phone:	Gi	oup #.	Rx Insurance Phone:	Group #:							
Subscriber: Other – Name:	Date of Birth: Relationship to Patient:										
Secondary Insurance Name (if a	Secondary Insurance ID# (if applicable):										
Secondary Insurance Phone:	Group#:										
Subscriber: Other - Name:			Date of Birth:	of Birth: Relationship to Patient:							
3 PAREN	T/CAREGIVER/I	EGAL REPRESENTATIVE	SIGNATURE(S)								
J TAKEN	I, CARLOIVER, E	EGAL KEI KESENTATIVE	- SIGNATORE(S)								
PATIENT AUTHORIZATION											
I authorize my healthcare providers, pharmacies, and health plan(s) to disclose my personal health information on this form as well as information related to my medical condition, treatment, care management, prescriptions, and health insurance to Teva Pharmaceuticals, Inc. and its affiliates, contractors and											
agents, including their third party patient support program service provider (collectively "Teva") for the purposes described below.											
I understand that the purpose of this Authorization is to provide me with access to services related to my prescribed medication and/or medical condition ("Program"), including (i) enrollment in the Program; (ii) conducting benefits investigation and coordinating my insurance coverage, which may include											
allowing a Teva field based representative to access my information and engage with my healthcare provider directly, if necessary; (iii) if needed,											
determining my eligibility for and coordinating financial assistance; (iv) coordinating prescription fulfillment and product replacement; (v) providing nursing support; (vi) facilitating quality and adverse event reporting activities; (vii) conducting data analytics, market research, and Program related											
business activities; (viii) contacting me by direct mail or by electronic or telephonic means to the contact information on this form or to any future contact											
information provided by me or on my behalf in connection with carrying out the Program services, including adherence related communications, reminders, and support, for which the third party service provider may receive financial remuneration from the manufacturer of your medication.											
I understand that I may cancel this Authorization at any time, by writing to Teva, Attn: Authorizations, P.O. Box 501847, San Diego, CA 92150-1847, but my											
cancellation will not apply to any information already disclosed pursuant to this Authorization. This Authorization will remain in effect until the Program ends. I understand that once my information is disclosed, it may be subject to redisclosure by the recipients and no longer protected by federal privacy law.											
I understand that my treatment, payment for treatment, insurance enrollment, or eligibility for insurance benefits will not be directly affected if I do not sign this Authorization. However, if I do not sign this Authorization, I may not be able to receive Program services. I am also entitled to a copy of this signed											
Authorization.	wever, ii i do not sign	this Authorization, I may not be	able to receive Program sei	rvices. i am ai	iso entitled t	o a copy or this signed					
PARENT/CAREGIVER/LE			e Patient Δuthorization La	uthorize all (	disclosures a	access to services					
As the patient's parent or legal guardian, I have read and understand the above Patient Authorization. I authorize all disclosures, access to services, and cancellation conditions outlined in the Patient Authorization above on behalf of the patient. I attest to possessing the legal authority to make											
these authorizations on b	ehalf of the patient.										
Parent/Caregiver/Legal	Rep Signature:			Date:							
Print name and relationship	0:										

# **PEDIATRIC** PRESCRIPTION AND SERVICE REQUEST FORM SIMLANDI® (adalimumab-ryvk) injection

### **ENROLLMENT FORM**

**teva** | **Shared Solutions**® for Biosimilars

PLEASE FAX COMPLETED FORM TO 866-676-4073 FOR QUESTIONS, CALL **888-587-3263** MONDAY-FRIDAY 9AM EST TO 7PM EST

4 PHYSICIAN INFORMATION (PHYSICIAN TO COMPLETE SECTIONS 4-6)												
Physician Name:	NPI#:		Tax ID #:									
Office Contact Name:	Contact Phone:	Contact Fax:	Contact Fax:									
Practice/Facility Name: Contact Email:												
Address:	City:	tate: ZIP:										
5 PRESCRIPTION IN	FORMATION											
Patient Name (First MI Last):	DOB (mm/dd/yyyy): Weight: ☐lbs ☐kg											
□ New □ Switch □ Restart												
DIAGNOSIS   Juvenile Idiopathic Arthritis   Pediatric Crohn's Disease												
PHARMACY PRESCRIPTION Please select the medication, and complete and sign the corresponding pharmacy prescription												
Patient's preferred Specialty Pharmacy*												
Pharmacy Phone: Pharmacy Fax:												
INDICATION	 e				Maintenance Dose							
Available SIMLANDI Formulations: Autoinjector 40 mg and 80 mg, Prefilled Syringe 20 mg and 40 mg												
JUVENILE IDIOPATHIC ARTHRITIS in patients	maintenance dose.		very other wee	ek								
15 kg (33 lbs) to less than 30 kg (66 lbs)			☐ Prefilled Syringe Refills:									
JUVENILE IDIOPATHIC ARTHRITIS in patients		☐ 40 mg SC (		very other week								
30 kg (66 lbs) and greater	Initial dose not required. Indicate maintenance dose.		□Autoinjector □ Prefilled Syringe Refills:									
DEDIATRIC CROUN'S DISEASE in patients	0 ma SC on Day 15	□ 20 mm = CC m		-144-								
PEDIATRIC CROHN'S DISEASE in patients 17 kg (37 lbs) to less than 40 kg (88 lbs)	☐ 80 mg SC on Day 1, followed 4 ☐ Autoinjector ☐ Prefilled Syring		very otner wee ringe	ry other week starting on Day 29 ge Refills:								
	, (ex tab) to tab than to ug (ex tab)											
PEDIATRIC CROHN'S DISEASE in patients	by 80 mg SC on Day 15	_	other week starting on Day 29									
40 kg (88 lbs) and greater	☐ Autoinjector ☐ Prefilled Syring	Prefilled Syri				ringe Refills:						
6 PRESCRIBER SIG	NATURE											
After discussing the Program for mu presc	ribed medication and/or medical co	ondition (including its age	ents. service provi	iders. and disr	oensina r	harmacies)						
After discussing the Program for my prescribed medication and/or medical condition (including its agents, service providers, and dispensing pharmacies) with the patient, the patient has elected to participate in the Program. I authorize the release of medical and/or other patient information relating to therapy												
to this Program, Teva Pharmaceuticals, Inc., its affiliates and its designated agents and service providers (collectively, "Teva"), to use and disclose as needed for fulfillment of the prescription related to this Program, and furnish any information in this form to the insurer of the above-named patient. I understand												
that Teva reserves the right to modify or terminate this Program at any time for any reason without any prior notice. I understand that I am under no												
obligation to prescribe a specific drug and I have not received, nor will I receive any benefit, for prescribing a specific drug. I certify that I have a signed copy on file of my patient's current and completed Patient Authorization so that I may share this patient's health information with Teva.												
**STAMP SIGNATURE NOT PERMITTED – INK SIGNATURE ONLY. Please attach all prescriptions on Official State Prescription form if mandated by individual												
state laws**  The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, or hard copy												
prescription, etc.												
Prescriber Signature:				Date:								
	2 3.00.											
Prescriber Signature:	Date:	Date:										

Substitution Permitted